Please use this identifier to cite or link to this item: http://cmuir.cmu.ac.th/jspui/handle/6653943832/54133
Title: Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
Authors: Tony Mok
Yi Long Wu
Jin Soo Lee
Chong Jen Yu
Virote Sriuranpong
Jennifer Sandoval-Tan
Guia Ladrera
Sumitra Thongprasert
Vichien Srimuninnimit
Meilin Liao
Yunzhong Zhu
Caicun Zhou
Fatima Fuerte
Benjamin Margono
Wei Wen
Julie Tsai
Matt Truman
Barbara Klughammer
David S. Shames
Lin Wu
Keywords: Biochemistry, Genetics and Molecular Biology
Medicine
Issue Date: 15-Jul-2015
Abstract: © 2015 American Association for Cancer Research. Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and blood samples from the FASTACT-2 study. Experimental Design: Patients were randomized to receive six cycles of gemcitabine/platinum plus sequential erlotinib or placebo. EGFR mutation testing was performed using the cobas tissue test and the cobas blood test (in development). Blood samples at baseline, cycle 3, and progression were assessed for blood test detection rate, sensitivity, and specificity; concordance with matched tumor analysis (n = 238), and correlation with progressionfree survival (PFS) and overall survival (OS). Results: Concordance between tissue and blood tests was 88%, with blood test sensitivity of75%and a specificity of 96%. Median PFS was 13.1 versus 6.0 months for erlotinib and placebo, respectively, for those with baseline EGFR mut+ cfDNA [HR, 0.22; 95% confidence intervals (CI), 0.14-0.33, P < 0.0001] and 6.2 versus 6.1 months, respectively, for the EGFR mut-cfDNA subgroup (HR, 0.83;95%CI, 0.65-1.04, P=0.1076). For patients with EGFR mut+ cfDNA at baseline, median PFS was 7.2 versus 12.0 months for cycle 3 EGFR mut+ cfDNA versus cycle 3 EGFR mut-patients, respectively (HR, 0.32; 95% CI, 0.21-0.48, P < 0.0001); median OS by cycle 3 status was 18.2 and 31.9 months, respectively (HR, 0.51; 95% CI, 0.31-0.84, P = 0.0066). Conclusions: Blood-based EGFR mutation analysis is relatively sensitive and highly specific. Dynamic changes in cfDNA EGFR mutation status relative to baseline may predict clinical outcomes.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84938399710&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/54133
ISSN: 15573265
10780432
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.


Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.